DGIdb - TOFACITINIB Drug Record

TOFACITINIB chembl:CHEMBL221959 ApprovedImmunotherapy

Alternate Names:

CP-690
550
CP-690,550 FREE BASE
CP-690550 FREE BASE
CP690550
CP-690-550
CP- 690 550
CP 690550
CP-690,550
CP-690550
TASOCITINIB
CP690,550
TOFACITINIB
XELJANZ®
rxcui:1357536
chemidplus:477600-75-2
drugbank:08895
pubchem.compound:9926791
chembl:CHEMBL221959

Drug Info:

Drug Categories	selective immunosuppressants
Drug Categories	janus kinase 3, antagonists & inhibitors
Drug Categories	antirheumatic agents
Drug Categories	bradycardia-causing agents
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 substrates
Drug Categories	disease-modifying antirheumatic agents
Drug Categories	janus kinase inhibitor
Drug Categories	janus kinase inhibitors

(3 More Sources)

Publications:

Changelian PS et al., 2003, Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor., Science
Jiang JK et al., 2008, Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)., J Med Chem
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
Jang WD et al., 2015, Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design., Bioorg Med Chem Lett
Tan L et al., 2015, Development of Selective Covalent Janus Kinase 3 Inhibitors., J Med Chem
Hou S et al., 2014, Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6., J Med Chem
Losdyck et al., 2015, Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities., J. Biol. Chem.
Koo et al., 2012, Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma., Cancer Discov
Elliott et al., 2011, FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma., Blood
Degryse et al., 2014, JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model., Blood
Yin et al., 2015, Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia., Leuk. Lymphoma

TOFACITINIB STAT5A

Interaction Score: 9.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14593182 19053756

Sources:
DTC
TOFACITINIB STAT5B

Interaction Score: 4.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14593182

Sources:
DTC
TOFACITINIB PTPN6

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24978112

Sources:
DTC
TOFACITINIB JAK3

Interaction Score: 1.61

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
14593182 26446793 22705984 21821710 25193870 26258521 10592235 25146434

Sources:
DTC JAX-CKB CIViC TTD DrugBank GuideToPharmacology
TOFACITINIB PKN1

Interaction Score: 1.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology
TOFACITINIB TYK2

Interaction Score: 0.96

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
10592235 26231159

Sources:
DTC DrugBank GuideToPharmacology
TOFACITINIB JAK1

Interaction Score: 0.57

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction In a biochemical enzyme assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
10592235

Sources:
DrugBank GuideToPharmacology
TOFACITINIB JAK2

Interaction Score: 0.4

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
26258521 10592235

Sources:
DTC DrugBank GuideToPharmacology
TOFACITINIB YES1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB08895
- Version: 5.1.7
Alternate Names:

TOFACITINIB DrugBank Drug Name

477600-75-2 CAS Number

Xeljanz Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

DTC: TOFACITINIB

Version: 02-September-2020

Alternate Names:

CHEMBL221959 ChEMBL Drug ID

Drug Info:

Publications:

Changelian PS et al., 2003, Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor., Science

Jiang JK et al., 2008, Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)., J Med Chem

Tan L et al., 2015, Development of Selective Covalent Janus Kinase 3 Inhibitors., J Med Chem

JAX-CKB: Tofacitinib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Losdyck et al., 2015, Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities., J. Biol. Chem.

Koo et al., 2012, Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma., Cancer Discov

Elliott et al., 2011, FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma., Blood

CIViC: TOFACITINIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Degryse et al., 2014, JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model., Blood
GuideToPharmacology: 178102304
- Version: 29-September-2020
Alternate Names:

TOFACITINIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Tofacitinib
- Version: 2020.06.01
Alternate Names:

D0EG1I TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL221959
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

Details of the Assay for Interaction	In a biochemical enzyme assay.
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

TOFACITINIB	DrugBank Drug Name
477600-75-2	CAS Number
Xeljanz	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

antagonist (inhibitory)
inhibitor (inhibitory)

TOFACITINIB Drug Record

TOFACITINIB chembl:CHEMBL221959 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14593182 19053756

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14593182

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24978112

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

PMIDs: 14593182 26446793 22705984 21821710 25193870 26258521 10592235 25146434

Sources: DTC JAX-CKB CIViC TTD DrugBank GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 10592235 26231159

Sources: DTC DrugBank GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Details of the Assay for Interaction In a biochemical enzyme assay. Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 10592235

Sources: DrugBank GuideToPharmacology

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 26258521 10592235

Sources: DTC DrugBank GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

DrugBank: DB08895

Alternate Names: TOFACITINIB DrugBank Drug Name 477600-75-2 CAS Number Xeljanz Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Groups investigational

Publications: Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

DTC: TOFACITINIB

Alternate Names: CHEMBL221959 ChEMBL Drug ID

Drug Info:

JAX-CKB: Tofacitinib

Alternate Names:

Drug Info:

CIViC: TOFACITINIB

Alternate Names:

Drug Info:

Publications: Degryse et al., 2014, JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model., Blood

GuideToPharmacology: 178102304

Alternate Names: TOFACITINIB GuideToPharmacology Ligand Name

Drug Info:

Publications:

TTD: Tofacitinib

Alternate Names: D0EG1I TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL221959

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
14593182 19053756

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
14593182

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
24978112

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
14593182 26446793 22705984 21821710 25193870 26258521 10592235 25146434

Sources:
DTC JAX-CKB CIViC TTD DrugBank GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
10592235 26231159

Sources:
DTC DrugBank GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction In a biochemical enzyme assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
10592235

Sources:
DrugBank GuideToPharmacology

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
26258521 10592235

Sources:
DTC DrugBank GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

TOFACITINIB DrugBank Drug Name

477600-75-2 CAS Number

Xeljanz Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

Alternate Names:

CHEMBL221959 ChEMBL Drug ID

Publications:

Degryse et al., 2014, JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model., Blood

Alternate Names:

TOFACITINIB GuideToPharmacology Ligand Name

Alternate Names:

D0EG1I TTD Drug ID